The assessment of treatment response is crucial for patient management since it guides
further treatment or surveillance program. For the purpose of response evaluation in …

Background: Positron emission tomography (PET) with the use of 18F-fluorodeoxyglucose
(FDG), implemented with low-dosage computer tomography, is to be considered as the most …

Our aim was to evaluate Hodgkin Lymphoma (HL) response to checkpoint inhibitors with
18F-FDG PET/CT. Forty three refractory or relapsed HL patients were investigated before …

The response evaluation criteria in patients with Hodgkin lymphoma (HL) were designed for
the assessment of chemotherapy and targeted molecular agents. We investigated the …

The development of immunotherapy has revolutionized cancer treatment, improving the
outcome and survival of many patients. Immune checkpoint inhibitors (ICIs), the most …

Background CT and fluorine 18 (18F) fluorodeoxyglucose (FDG) PET/CT performances
following immune therapy are not well known in patients with relapsed or refractory Hodgkin …

Introduction Patients with relapsed/refractory Hodgkin lymphoma (R/R HL) experience high
response rates upon anti-PD1 therapy. In these patients, the optimal duration of treatment …

Background The combination of anti-programmed death-1 antibodies and chemotherapy is
effective; however, there are no reliable outcome prediction factors. We investigated the …

Recent advances in the management of Hodgkin lymphoma, due to new staging and
response assessment systems as well as new therapies, have redefined the role of imaging …

Immune checkpoint inhibitors are currently the standard of care for many advanced solid
tumors, and they have been recently approved for the treatment of relapsed/refractory …